Novel approaches to the treatment of small-cell lung cancer

Cellular and Molecular Life Sciences

Volumn 55, Issue 12, 1999, Pages 1585-1598

  Zangemeister Wittke, U ^a   Stahel, R A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibodies; Antisense; Chemotherapy; Growth factor inhibitors; Small cell lung cancer

Indexed keywords

CANCER ANTIBODY; CARBOPLATIN; CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GANGLIOSIDE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IFOSFAMIDE; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2; SOMATOMEDIN C; TENIPOSIDE; TUMOR ANTIGEN; VINCRISTINE; VINDESINE;

APOPTOSIS; BLOOD GROUP LEWIS SYSTEM; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG TARGETING; GENE THERAPY; HUMAN; LUNG SMALL CELL CANCER; ONCOGENE; ONCOGENE MYC; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SMALL CELL; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LUNG NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0032831540     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050398     Document Type: Review

References (162)

1. Boring C. C., Squires T. S., Tong T. and Montgomery S. (1994) Cancer statistics, 1994. CA Cancer J. Clin. 44: 7-26
2. Zelen M. (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother. Rep. 4: 31-42
3. Souhami R. L. and Law K. (1990) Longevity in small cell lung cancer: a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br. J. Cancer 61: 584-589
4. Miller A. B., Fox W. and Tall R. (1969) Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet ii: 501-505
5. Fox W. and Seadding J. G. (1973) Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: ten-year follow-up. Lancet ii: 63-65
6. Ihde D. C. (1992) Chemotherapy of lung cancer. N. Engl. J. Med. 327: 1434-1441
7. Souhami R. L., Rudd R., Ruiz-de E. M., James L., Gower N., Harper P. G. et al. (1994) Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J. Clin. Oncol. 12: 1806-1813
8. Ihde D. C., Mulshine J. L., Kramer B. S., Steinberg S. M., Linnoila R. I., Gazdar A. F. et al. (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12: 2022-2034
9. Pujol J. L., Douillard J. Y., Riviere A., Quoix E., Lagrange J. L., Berthaud P. et al. (1997) Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J. Clin. Oncol. 15: 2082-2089
10. Maurer L. H., Herndon J. E. H, Hollis D. R., Aisner J., Carey R. W., Skarin A. T. et al. (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J. Clin. Oncol. 15: 3378-3387
11. Kelly K., Crowley J. J., Bunn-PA J., Hazuka M. B., Beasley K., Upchurch C. et al. (1995) Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Croup study. J. Clin. Oncol. 13: 2924-2930
12. Rowland K. M. J., Loprinzi C. L., Shaw E. G., Maksymiuk A. W., Kuross S. A., Jung S. H. et al. (1996) Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J. Clin. Oncol. 14: 135-141
13. Ettinger D. S., Finkelstein D. M., Sarma R. P. and Johnson D. H. (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 13: 1430-1435
14. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Goss G. et al. (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): a study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 5: 283-285
15. Furuse K., Kubota K., Kawahara M., Takada M., Kimura I., Fujii M. et al. (1996) Phase II study of vinorelbine in heavily previously treated small cell lung cancer: Japan Lung Cancer Vinorelbine Study Group. Oncology 53: 169-172
16. Schiller J. H., Kim K., Hutson P., DeVore R., Glick J., Stewart J. et al. (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 14: 2345-2352
17. Pignon J. P., Arrigada R., Ihde D. C., Johnson D. H., Perry M. C., Souhami R. L. et al. (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327: 1618-1624
18. Turrisi A., Kyungmann K., Blum R., Sause W. T., Livingston R. B., Komaki R. et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340: 265-271
19. Arriagada R., Le C. T., Borie F., Riviere A., Chomy P., Monnet I. et al. (1995) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer Inst. 87: 183-190
20. Arriagada R., Auperin A., Pignon J. P., Gregor A., Stephens R., Kristjansen P. E. G. et al. (1998) Prophylactic cranial irradiation overview (PCIO) in patients with small cell lung cancer (SCLC) in complete remission (CR) (Abstract no. 1758). Proc. Am. Soc. Clin. Oncol. 17.
21. Gregor A., Cull A., Stephens R. J., Kirkpatrick J. A., Yarnold J. R., Girling D. J. et al. (1997) Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur. J. Cancer 33: 1752-1758
22. Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D. et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2, neu monoclonal antibody plus cisplatin in patients with HER2 neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16: 2659-2671
23. Yang D. J., Kuan C. T., Payne J., Kihara A., Murray A., Wang L. M. et al. (1998) Recombinant heregulin Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Clin. Cancer Res. 4: 993-1004
24. Colcher D., Bird R., Roselli M., Hardman K. D., Johnson S., Pope S. et al. (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 82: 1191-1197
25. Begent R. H., Verhaar M. J., Chester K. A., Casey J. L., Green A. J., Napier M. P. et al. (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2: 979-984
26. Dolman C. S., Mueller B. M., Lode H. N., Xiang R., Gillies S. D. and Reisfeld R. A. (1998) Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin. Cancer Res. 4: 2551-2557
27. Souhami R. L., Beverley P. C., Bobrow L. G. and Ledermann J. A. (1991) Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J. Natl. Cancer Inst. 83: 609-612
28. Stahel R. A., Gilks W. R. and Schenker T. (1994) Antigens of lung cancer: results of the Third International Workshop on Lung Tumor and Differentiation Antigens. J. Natl. Cancer Inst. 86: 669-672
29. Zangemeister W. U., Lehmann H. P., Waibel R., Wawrzynczak E. J. and Stahel R. A. (1993) Action of a CD24-specific deglycosylated ricin-A-chain immunotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int. J. Cancer 53: 521-528
30. Waibel R., Mannhart M., O'Hara C. J., Brocklehurst C., Zangemeister W. U., Schenker T. et al. (1993) Monoclonal antibody SEN7 recognizes a new epitope on the neural cell adhesion molecule present on small cell lung cancer but not on lymphocytes. Cancer Res. 53: 2840-2845
31. Ledermann J. A., Marston N. J., Stahel R. A., Waibel R., Buscombe J. R. and Ell P. J. (1993) Biodistribution and tumour localisation of 1311 SWAH recognising the cluster w4 antigen in patients with small cell lung cancer. Br. J. Cancer 68: 119-121
32. Ornadel D., Ledermann J. A., Eagle K., Pedley R. B., Boxer G., Ward S. E. et al. (1998) Biodistribution of a radiolabelled monoclonal antibody NY3DH recognizing the neural cell adhesion molecule in tumour xenografts and patients with small cell lung cancer. Br. J. Cancer 77: 103-109
33. Doria M. I. J., Montag A. G. and Franklin W. A. (1988) Immunophenotype of small cell lung carcinoma: expression of NKH-1 and transform receptor and absence of most myeloid antigens. Cancer 62: 1939-1945
34. Skarin A. T. (1993) Analysis of long-term survivors with small-cell lung cancer. Chest 103: 440S-444S
35. Mechtersheimer G., Staudter M. and Moller P. (1991) Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res. 51: 1300-1307
36. Hosono M. N., Hosono M., Endo K., Ueda R. and Onoyama Y. (1994) Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J. Nuclear Med. 35: 504-509
37. Lynch T. J. L., Lambert J. M., Coral F., Shefner J., Wen P., Blattler W. A. et al. (1997) Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J. Clin. Oncol. 15: 723-734
38. Strand J., Hamilton A. E., Beavers L. S., Gamboa G. C., Apelgren L. D., Taber L. D. et al. (1989) Molecular cloning and characterization of a human adenocarcinoma epithelial cell surface antigen complementary DNA. Cancer Res. 49: 314-317
39. Zimmermann S., Wels W., Froesch B. A., Gerstmayer B., Stahel R. A. and Zangemeister Wittke U. (1997) A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol. Immunother. 44: 1-9
40. Basak S., Speicher D., Eck S., Wunner W., Maul G., Simmons M. S. et al. (1998) Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J. Natl. Cancer Inst. 90: 691-697
41. Cirulli V., Crisa L., Beattie G. M., Mally M. I., Lopez A. D., Fannon A. et al. (1998) KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J. Cell Biol. 140: 1519-1534
42. Reithmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K. et al. (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome or a multicenter randomized trial. J. Clin. Oncol. 16: 1788-1794
43. Kosterink J. G., Jonge M. W. de, Smit E. F., Piers D. A., Kengen R. A., Postmus P. E., et al. (1995) Pharmacokinetics and scintigraphy of indium-H1-DTPA-MOC-31 in small-cell lung carcinoma, J. Nuclear Med. 36: 2356-2362
44. Willuda J., Honegger A., Waibel R., Stahel R., Zangemeister-Wittke U. and Plückthun A. (1999) Rational engineering for high stability is required for tumor targeting of a high-affinity scFv fragment specific for the panepithelial glycoprotein EGP-2 (EP-CAM). Proc. Am. Assoc. Cancer Res. 40: 354
45. Ura Y., Dion A. S., Williams C. J., Olsen B. D., Redfield E. S., Ishida M. et al. (1992) Quantitative dot blot analyses of blood-group-related antigens in paired normal and malignant human breast tissues. Int. J. Cancer 50: 57-63
46. Cooper H. S., Malecha M. J., Bass C., Fagel P. L. and Steplewski Z. (1991) Impression of blood group antigens H-2. Le(y), and sialylated-Le(a) in human colorectal carcinoma: an immunohistochemical study using double-labeling techniques. Am. J. Pathol. 138: 103-110
47. Murata K., Egami H., Shibata Y., Sakamoto K., Misumi A. and Ogawa M. (1992) Expression of blood group-related antigens, ABH, Lewis(a), Lewis(b), Lewis(x), Lewis(y), CA19-9, and CSLEXI in early cancer, intestinal metaplasia, and uninvolved mucosa of the stomach. Am. J. Clin. Pathol. 98: 67-75
48. Leoni F., Colnaghi M. I., Canevari S., Menard S., Colzani E., Facheris P. et al. (1992) Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuCl. Int. J. Cancer 51: 225-231
49. Miyake M., Taki T., Hitomi S. and Hakomori S. (1992) Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N. Engl. J. Med. 327: 14-18
50. Miyake M., Zenita K., Tanaka O., Okada Y. and Kannagi R. (1988) Stage-specific expression of SSEA-1-related antigens in the developing lung of human embryos and its relation to the distribution of these antigens in lung cancers. Cancer Res. 48: 7150-7158
51. Stahel R. A., Lacroix H., Sculier J. P., Morant R., Richner J., Janzek E. et al. (1992) Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. Ann. Oncol. 3: 319-320
52. Siegall C. B. (1995) Targeted therapy of carcinomas using BR96 sFv-PE-40, a single-chain immunotoxin that binds to the Le(y) antigen. Semin. Cancer Biol. 6: 289-295
53. Pai L. H., Wittes R., Setser A., Willingham M. C. and Pastan I. (1996) Treatment of advanced solid tumors with immunotoxin LMB-I: an antibody linked to Pseudomonas exotoxin. Nat. Med. 2: 350-353
54. Pastan I. H., Pai I., H., Brinkmann U. and Fitzgerald D. J. (1995) Recombinant toxins: new therapeutic agents for cancer. Ann. NY Acad. Sci. 758: 345-354
55. Cheresh D. A., Pierschbacher M. D., Herzig M. A. and Mujoo K. (1986) Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J. Cell Biol. 102: 688-696
56. Cheresh D. A., Honsik C. J., Staffileno L. K., Jung G. and Reisfeld R. A. (1985) Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc. Natl. Acad. Sci. USA 82: 5155-5159
57. Fuentes R., Allman R. and Mason M. D. (1997) Ganglioside expression in lung cancer cell lines. Lung Cancer 18: 21-33
58. Hanibuchi M., Yano S., Nishioka Y., Yanagawa H. and Sone S. (1996) Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes. Jpn. J. Cancer Res. 87: 497-504
59. Houghton A. N., Mintzer D., Cordon C. C., Welt S., Fliegel B., Vadhan S. et al. (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82: 1242-1246
60. Cheung N. K. and Miraldi F. D. (1988) Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma. Prog. Clin. Biol. Res. 271: 595-604
61. Grant S. C., Kostakoglu L., Kris M. G., Yeh S. D., Larson S. M., Finn R. D. et al. (1996) Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur. J. Nuclear Med. 23: 145-149
62. Kris M. G. and Miller V. (1997) Long-term survival in 15 patients with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: an update. Proc. Am. Soc. Clin. Oncol. 16: 1630
63. Sporn M. B. and Todaro G. J. (1980) Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303: 878-880
64. Carney D. N., Gazdar A. F., Bepler G., Guccion J. G., Marangos P. J., Moody T. W. et al. (1985) Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923
65. Sausville E. A., Lebacq V. A., Spindel E. R., Cuttitta F., Gazdar A. F. and Battey J. F. (1986) Expression of the gastrin-releasing peptide gene in human small cell lung cancer: evidence for alternative processing resulting in three distinct mRNAs. J. Biol. Chem. 261: 2451-2457
66. Spindel E. R., Zilberberg M. D. and Chin W. W. (1987) Analysis of the gene and multiple messenger ribonucleic acids (mRNAs) encoding human gastrin-releasing peptide: alternate RNA splicing occurs in neural and endocrine tissue. Mol. Endocrinol. 1: 224-232
67. Heikkila R., Trepel J. B., Cuttitta F., Neckers L. M. and Sausville E. A. (1987) Bombesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines. J. Biol. Chem. 262: 16456-16460
68. Moody T. W., Murphy A., Mahmoud S. and Fiskum G. (1987) Bombesin-like peptides elevate cytosolic calcium in small cell lung cancer cells. Biochem. Biophys. Res. Commun. 147: 189-195
69. Jones C. L., Beck L. K., Brozna J. P., Holley M., Dempsey E. J. and Kane M. A. (1995) Properties of classic protein kinase C in human small cell lung carcinoma NCI-H345 cells. Cell Growth Differ. 6: 1627-1634
70. Bepler G., Zeymer U., Mahmoud S., Fiskum G., Palaszynski E., Rotsch M. et al. (1988) Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372
71. Kelley M. J., Linnoila R. I., Avis I. L., Georgiadis M. S., Cuttitta F., Mulshine J. L. et al. (1997) Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112: 256-261
72. Nakanishi Y., Mulshine J. L., Kasprzyk P. G., Natale R. B., Maneckjee R., Avis I. et al. (1988) Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J. Clin. Invest. 82: 354-359
73. Reeve J. G., Xiong J., Morgan J. and Bleehen N. M. (1996) Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer 73: 1193-1200
74. Minuto F., Del M. P., Barreca A., Alama A., Cariola G. and Giordano G. (1988) Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line. Cancer Res. 48: 3716-3719
75. Rechler M. M. and Nissley S. P. (1985) The nature and regulation of the receptors for insulin-like growth factors. Annu. Rev. Physiol. 47: 425-442
76. Kauffmann Z. A., Rodriguez V. P., Ulrich E., Gilbert C. Coffer P., Downward J. et al. (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544-548
77. Dudek H., Datta S. R., Franke T. F., Birnbaum M. J., Yao R., Cooper G. M. et al. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665
78. Minshall C., Arkins S., Strata J., Conners J., Dantzer R., Freund G. G. et al. (1997) IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J. Immunol. 159: 1225-1232
79. Baserga R., Hongo A., Rubini M., Prisco M. and Valentinis B. (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1332: F105-F126
80. Zia F., Jacobs S., Kull F., Cuttitta F., Mulshine J. L. and Moody T. W. (1996) Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J. Cell Biochem. Suppl. 24: 269-275
81. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S. and Baserga R. (1994) Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54: 4848-4850
82. Crooke S. T. (1998) An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. 8: 115-122
83. Crooke S. T. (1998) Basic principles of antisense therapeutics. Antisense Res. Appl. 131: 1-50
84. Bennett C. F. (1998) Antisense oligonucleotides: is the glass half full or half empty? Biochem. Pharmacol. 55: 9-19
85. Ziegler A., Luedke G. H., Fabbro D., Altmann K. H. and Zangemeister-Wittke U. (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst. 89: 1027-1036
86. Monia B. P., Sasmor H., Johnston J. F., Freier S. M., Lesnik E. A., Muller M. et al. (1996) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf Kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93: 15481-15484
87. Skorski T., Nieborowska Skorska M., Wlodarski P., Perrotti D., Hoser G., Kawiak J. et al. (1997) Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and ber/abl antisense oligodeoxynucleotides. J. Natl. Cancer Inst. 89: 124-133
88. Zaman G. J., Versantvoort C. H., Smit J. J., Eijdems E. W., Haas M. de, Smith A. J. et al. (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53: 1747-1750
89. Narasaki F., Matsuo I., Ikuno N., Fukuda M., Soda H. and Oka M. (1996) Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res. 16: 2079-2082
90. Poupon M. F., Arvelo F., Goguel A. F., Bourgeois Y., Jacrot M., Hanania N. et al. (1993) Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J. Natl. Cancer Inst. 85: 2023-2029
91. Lai S. L., Goldstein L. J., Gottesman M. M., Pastan I., Tsai C. M., Johnson B. E. et al. (1989) MDR1 gene expression in lung cancer. J. Natl. Cancer Inst. 81: 1144-1150
92. Alahari S. K., DeLong R., Fisher M. H., Dean N. M., Viliet P. and Juliano R. L. (1998) Novel chemically modified oligonucleotides, provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 286: 419-428
93. Bishop J. M. (1991) Molecular themes in ontogenesis. Cell 64: 235-248
94. Weinberg R. A. (1991) Tumor suppressor genes. Science 254: 1138-1146
95. Vogelstein B. and Kinder K. W. (1992) p53 function and dysfunction. Cell 70: 523-526
96. Fisher D. E. (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542
97. Smets L. A. (1994) Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs 5: 3-9
98. Reed J. C. (1997) Double identity for proteins of the Bcl-2 family. Nature 387: 773-776
99. Adams J. M. and Cory S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326
100. Simonian P. L., Grillot D. A. and Nunez G. (1997) Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216
101. Ikegaki N., Katsumata M., Minna J. D. and Tsujimoto Y. (1994) Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 54: 6-8
102. Jiang S. X., Sato Y., Kuwao S. and Kameya T. (1995) Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol. 177: 135-138
103. Ben Ezra J. M., Kornstein M. J., Grimes M. M. and Krystal C. (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am. J. Pathol. 145: 1036-1040
104. Zangemeister-Wittke U., Schenker T., Luedke G. H. and Stahel R. A. (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small cell lung cancer cell lines. Br. J. Cancer 78: 1035-1042
105. Webb A., Cunningham D., Cotter F., Clarke P. A., Distefano F., Ross P. et al. (1997) Bcl-2 antisense therapy in patients with non-Hodgkin-lymphoma. Lancet 49: 1137-1141
106. Guvakova M. A., Yakubov L. A., Vlodavsky I., Tonkinson J. L. and Stein C. A. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270: 2620-2627
107. Tuscano J. M., Druey K. M., Riva A., Pena J., Thompson C. B. and Kehrl J. H. (1996) Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood 88: 1359-1364
108. Dole M. G., Jasty R., Cooper M. J., Thompson C. B., Nunez G. and Castle V. P. (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55: 2576-2582
109. Wong A. J., Ruppert J. M., Eggleston J., Hamilton S. R., Baylin S. B. and Vogelstein B. (1986) Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 233: 461-464
110. Prins J., De V. E. and Mulder N. H. (1993) The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 13: 1373-1385
111. Little C. D., Nau M. M., Carney D. N., Gazdar A. F. and Minna J. D. (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196
112. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M. et al. (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128
113. Sakamuro D., Eviner V., Elliott K. J., Showe L., White E. and Prendergast G. C. (1995) c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 11: 2411-2418
114. Thompson E. B. (1998) The many roles of c-Myc in apoptosis. Annu. Rev. Physiol. 60: 575-600
115. Alarcon R. M., Rupnow B. A., Gracber T. G., Knox S. J. and Giaccia A. J. (1996) Modulation of c-Myc activity and apoptosis in vivo. Cancer Res. 56: 4315-4319
116. Askew D. S., Ashmun R. A., Simmons B. C. and Cleveland J. L. (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922
117. Johnson B. E., Russell E., Simmons A. M., Phelps R., Steinberg S. M., Ihde D. C. et al. (1996) MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J. Cell Biochem. Suppl. 24: 210-217
118. Bergh J. C. (1990) Gene amplification in human lung cancer: the myc family genes and other proto-oncogenes and growth factor genes. Am. Rev. Respir. Dis. 142: S20-S26
119. Funa K., Steinholtz L., Nou E. and Bergh J. (1987) Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. Am. J. Clin. Pathol. 88: 216-220
120. Robinson L. A., Smith L. J., Fontaine M. P., Kay H. D., Mountjoy C. P. and Pirruccello S. J. (1995) c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann. Thorac. Surg. 60: 1583-1591
121. Kimura S., Maekawa T., Hirakawa K., Murakami A. and Abe T. (1995) Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 55: 1379-1384
122. Leonetti C., D'Agnano I., Lozupone F., Valentini A., Geiser T., Zon G. et al. (1996) Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst. 88: 419-429
123. Hunter T. and Pines J. (1994) Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79: 573-582
124. Donnellan R. and Chetty R. (1998) Cyclin D1 and human neoplasia. Mol. Pathol. 51: 1-7
125. Baldin V., Lukas J., Marcote M. J., Pagano M. and Draetta G. (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7: 812-821
126. Quelle D. E., Ashmun R. A., Shurtleff S. A., Kato J. Y., Bar S. D., Roussel M. F. et al. (1993) Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7: 1559-1571
127. Prall O. W., Rogan E. M. and Sutherland R. L. (1998) Estrogen regulation of cell cycle progression in breast cancer cells. J. Steroid Biochem. Mol. Biol. 65: 169-174
128. Hinds P. W., Dowdy S. F., Eaton E. N., Arnold A. and Weinberg R. A. (1994) Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA 91: 709-713
129. Lovec H., Sewing A., Lucibello F. C., Muller R. and Moroy T. (1994) Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323-326
130. Betticher D. C., Heighway J., Hasleton P. S., Altermatt H. J., Ryder W. D., Cerny T. et al. (1996) Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br. J. Cancer 73: 294-300
131. Betticher D. C., White G. R., Vonlanthen S., Liu X., Kappeler A., Altermatt H. J. et al. (1997) G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int. J. Cancer 74: 556-562
132. Schrump D. S., Chen A. and Consoli U. (1996) Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 3: 131-135
133. Shen R., Su Z. Z., Olsson C. A. and Fisher P. B. (1995) Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc. Natl. Acad. Sci. USA 92: 6778-6782
134. Sun Y., Lin J., Katz A. E. and Fisher P. B. (1997) Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res. 57: 18-23
135. Su Z. Z., Goldstein N. I. and Fisher P. B. (1998) Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc. Natl. Acad. Sci. USA 95: 1764-1769
136. Ullrich S. J., Anderson C. W., Mercer W. E. and Appella E. (1992) The p53 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem. 267: 15259-15262
137. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B. and Craig R. W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311
138. Kuerbitz S. J., Plunkett B. S., Walsh W. V. and Kastan M. B. (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89: 7491-7495
139. Hansen R. and Oren M. (1997) p53: from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7: 46-51
140. Yin C., Knudson C. M., Korsmeyer S. J. and Van D. T. (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640
141. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A. et al. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805
142. Dameron K. M., Volpert O. V., Tainsky M. A. and Bouck N. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584
143. Bouvet M., Ellis L. M., Nishizaki M., Fujiwara T., Liu W. B., Bucana C. D. et al. (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58: 2288-2292
144. Goodrich D. W., Wang N. P., Qian Y. W., Lee E. Y. and Lee W. H. (1991) The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67: 293-302
145. Weintraub S. J., Prater C. A. and Dean D. C. (1992) Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358: 259-261
146. Wiman K. G. (1993) The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J. 7: 841-845
147. Roth J. A. (1998) Gene replacement strategies for lung cancer Curr. Opin. Oncol. 10: 127-132
148. Deiry W. S. el, Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
149. Harper J. W., Adami G. R., Wei N., Keyomarsi K. and Elledge S. J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
150. Waga S., Hannon G. J., Beach D. and Stillman B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578
151. Deng C., Zhang P., Harper J. W., Elledge S. J. and Leder P. (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684
152. Joshi U.S., Chen Y.Q., Kalemkerian G. P., Adil M. R., Kraut M. and Sarkar F. H. (1998) Inhibition of tumor cell growth by p21(WAF1) adenoviral gene transfer in lung cancer. Cancer Gene Ther. 5: 183-191
153. Ookawa K., Shiseki M., Takahashi R., Yoshida Y., Terada M. and Yokota J. (1993) Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 8:2175-2181
154. Demers G. W., Harris M. P., Wen S. F., Engler H., Nielsen L. L. and Maneval D. C. (1998) A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth. Cancer Gene Ther. 5: 207-214
155. Colombo M. P. and Forni G. (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15: 48-51
156. Schmidt W. G. and Schmidt W. I. (1995) Cytokines and clinical gene therapy. Eur. J. Immunol. 25: 1137-1140
157. Taniguchi T. (1992) Structure and function of IL-2 and IL-2 receptors. Behring Inst. Mitt. 87-95
158. Voss S. D., Sondel P. M. and Robb R. J. (1992) Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J. Exp. Med. 176: 531-541
159. Clamon G., Herndon J., Perry M. C., Ozer H., Kreisman H., Maher T. et al. (1993) Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J. Natl. Cancer Inst. 85: 316-320
160. Cassileth P. A., Podack E., Sridhar K., Savaraj N. and Hanlon J. (1995) Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum. Gene Ther. 6: 369-383
161. Meazza R., Marciano S., Sforzini S., Orengo A. M., Coppolecchia M., Musiani P. et al. (1996) Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer. Br. J. Cancer 74: 788-795
162. Niehans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J. et al. (1997) Human lung carcinomas express Fas ligand. Cancer Res. 57: 1007-1012